Open Lab facility for industry,
High-throughput screening of
small-molecules libraries identified
antibacterials against clinically
relevant multidrug-resistant
A. baumannii and K. pneumoniae
Excellent phase 2A results
of Q203 * (Telacebec)
presented at WHO
conference and published in AJRCCM
Mechanism of Q203 (Telacebec)
Gains Spotlight as a Core Strategy
for Tuberculosis Treatment
INSTITUT PASTEUR KOREA AT A GLANCE
-
- Korean Nonprofit Research Institute
- founded on international collaboration between Korea and France
-
- Tackling Diseases & Fighting Infections
- through basic and translational research based on innovative technology
-
- Member of the Pasteur Network
- consisting 33 institutes located in 25 countries worldwide
-
- Contributing to Global Public Health
- as Asia-Pacific regional hub for infectious diseases and global partner to international public health bodies
From Louis Pasteur of the 19th century to Institut Pasteur Korea of today, we are Pasteurians fighting diseases for everyone in the world
-
Areas of Expertise
-
Our Impact
-
Technology for All
-
Pasteurians
Stories to Share
-
Notice[Pasteur Network] Newsletter - October 2025
2025-11-03
FULL STORY
-
IPK in the News[Seongnam-si(2025.09.24)] Seongnam-si Selects 19 exemplary citizeens in 10 categories, including...
2025-10-01
FULL STORY
-
Notice[Pasteur Network] Newsletter - September 2025
2025-09-30
FULL STORY
-
Press ReleaseInstitut Pasteur Korea to Host “Breaking into Europe: Bio-Medical & Pharma Market Strategies” Forum
2025-09-25
FULL STORY
-
Education & Training[IPK 2023 Signature Training Course] High Content Screening for Therapeutics Discovery (Aug 28 ~...
2023-03-16
FULL STORY
-
Event & Seminar[AMR Seminar (Oct 7)] Accelerating the One Health Response on AMR
2022-10-07
FULL STORY
-
NoticeThe IPK CEO presented the Infectious Disease Research Innovation Strategy at the 2022 EKC
2022-07-29
FULL STORY
-
Press ReleaseInstitut Pasteur Korea organizes and hosts Pasteur Network teaching course: The Business of Mana...
2022-06-28
FULL STORY




